|
US6232445B1
(en)
*
|
1997-10-29 |
2001-05-15 |
Sunol Molecular Corporation |
Soluble MHC complexes and methods of use thereof
|
|
EP1124568B1
(de)
*
|
1998-10-21 |
2007-08-22 |
Altor BioScience Corporation |
Polyspezifische bindemoleküle und deren verwendung
|
|
EP2322228B1
(de)
*
|
2000-06-05 |
2018-01-10 |
Altor BioScience Corporation |
T-Zell-Rezeptor Fusionsproteine und Konjugate und Verfahren zu deren Verwendung
|
|
SG143058A1
(en)
*
|
2000-08-11 |
2008-06-27 |
Favrille Inc |
Method and composition for altering a t cell mediated pathology
|
|
DE10109855A1
(de)
*
|
2001-03-01 |
2002-09-12 |
Stanislawski Thomas |
Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
|
|
WO2004018619A2
(en)
|
2001-06-05 |
2004-03-04 |
Altor Bioscience Corporation |
P53 binding t cell receptor molecules and uses thereof
|
|
AU2003271904B2
(en)
*
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
GB0223399D0
(en)
*
|
2002-10-09 |
2002-11-13 |
Avidex Ltd |
Receptors
|
|
GB0226227D0
(en)
*
|
2002-11-09 |
2002-12-18 |
Avidex Ltd |
Receptors
|
|
EP2048159B1
(de)
|
2002-11-09 |
2014-01-01 |
Immunocore Ltd. |
T-Zellrezeptorpresentation
|
|
KR101131297B1
(ko)
*
|
2003-11-10 |
2012-03-30 |
알토 바이오사이언스 코포레이션 |
가용성 티씨알 분자 및 이용 방법
|
|
GB0411771D0
(en)
*
|
2004-05-26 |
2004-06-30 |
Avidex Ltd |
Nucleoproteins displaying native T cell receptor libraries
|
|
WO2006054096A2
(en)
*
|
2004-11-18 |
2006-05-26 |
Avidex Ltd |
Soluble bifunctional proteins
|
|
EP1878744A1
(de)
*
|
2006-07-13 |
2008-01-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
|
|
CN102321602B
(zh)
*
|
2011-07-27 |
2012-12-05 |
通化统博生物医药有限公司 |
β-内酰胺酶促进功能蛋白折叠的用途及融合蛋白的制备
|
|
ES2835200T3
(es)
*
|
2012-05-22 |
2021-06-22 |
Us Health |
Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
EP3137100B1
(de)
|
2014-04-15 |
2023-12-20 |
University Of Virginia Patent Foundation |
Isolierte t-zellenrezeptoren und verfahren zur verwendung davon
|
|
US11851469B2
(en)
|
2014-11-07 |
2023-12-26 |
Xlifesc, Ltd. |
Soluble heterodimeric T cell receptor, and preparation method and use thereof
|
|
KR20180043800A
(ko)
|
2015-09-09 |
2018-04-30 |
이뮨 디자인 코포레이션 |
Ny-eso-1 특이적 tcrs 및 그의 사용 방법
|
|
GB201520579D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520539D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520589D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520543D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
WO2018083505A1
(en)
|
2016-11-07 |
2018-05-11 |
Immunocore Limited |
Peptides
|
|
GB201520559D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201604468D0
(en)
|
2016-03-16 |
2016-04-27 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520558D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520557D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520564D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520548D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520603D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520592D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520562D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201607535D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520566D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520597D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520570D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520545D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520544D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520536D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520546D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520567D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
WO2017089786A1
(en)
|
2015-11-23 |
2017-06-01 |
Immunocore Limited |
Peptides
|
|
GB201607534D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520583D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520595D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520575D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
|
GB201520565D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520563D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520542D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520541D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
WO2017091905A1
(en)
*
|
2015-12-02 |
2017-06-08 |
Innovative Targeting Solutions Inc. |
Single variable domain t-cell receptors
|
|
GB201604953D0
(en)
|
2016-03-23 |
2016-05-04 |
Immunocore Ltd |
T cell receptors
|
|
IL308831A
(en)
|
2016-04-08 |
2024-01-01 |
Immunocore Ltd |
T cell receptors
|
|
EP3452499A2
(de)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Gentechnisch veränderte zellen und verfahren zur herstellung davon
|
|
JP7599819B2
(ja)
|
2016-06-02 |
2024-12-16 |
イムノコア リミテッド |
ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
|
|
JP7054397B2
(ja)
|
2016-06-27 |
2022-04-13 |
ジュノー セラピューティクス インコーポレイテッド |
Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
EP3525803B1
(de)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immuntherapieverfahren und zusammensetzungen mit tryptophan-stoffwechselweg-modulatoren
|
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃａｒ−ｔ細胞の調節方法
|
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
|
EP3571221A2
(de)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics GmbH |
Zelloberflächenkonjugate und verwandte zellzusammensetzungen und verfahren
|
|
EP3573997A4
(de)
*
|
2017-01-24 |
2020-12-09 |
Abexxa Biologics, Inc. |
Verfahren und zusammensetzungen zum targeting eines komplexes, der nicht klassisches hla-i und neoantigen umfasst, bei krebs
|
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
EP3592776A4
(de)
*
|
2017-03-08 |
2021-01-06 |
Agency for Science, Technology and Research |
T-zell-rezeptorähnliche antikörper, die an den p53-mhc-klasse-i-komplex binden
|
|
CN110913690A
(zh)
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
用于低温储存的方法
|
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
|
CN110709700A
(zh)
|
2017-04-14 |
2020-01-17 |
朱诺治疗学股份有限公司 |
评估细胞表面糖基化的方法
|
|
PL3618842T3
(pl)
|
2017-05-01 |
2024-02-19 |
Juno Therapeutics, Inc. |
Kombinacja terapii komórkowej i związku immunomodulującego
|
|
IL327498A
(en)
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3631468A1
(de)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Artikel zur herstellung und verfahren im zusammenhang mit der mit einer zelltherapie einherenden toxizität
|
|
GB201709866D0
(en)
|
2017-06-20 |
2017-08-02 |
Immunocore Ltd |
T cell receptors
|
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
|
EP4549554A3
(de)
|
2017-07-29 |
2025-08-06 |
Juno Therapeutics, Inc. |
Reagenzien zur expansion von zellen, die rekombinante rezeptoren exprimieren
|
|
EP4516896A3
(de)
|
2017-08-09 |
2025-05-14 |
Juno Therapeutics, Inc. |
Verfahren und zusammensetzungen zur herstellung genetisch manipulierter zellen
|
|
KR102755437B1
(ko)
|
2017-08-09 |
2025-01-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
CA3070468A1
(en)
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
CN107881185A
(zh)
*
|
2017-11-21 |
2018-04-06 |
重庆天科雅生物科技有限公司 |
一种单链tcr‑t载体及单链tcr‑t细胞生产工艺
|
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
BR112020011223A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
marcadores fenotípicos para terapia celular e mé-todos relacionados
|
|
JPWO2019151392A1
(ja)
*
|
2018-01-31 |
2021-02-04 |
国立大学法人東北大学 |
抗原特異的ｍｈｃ発現調節法
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
CN112585277A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
表达重组受体的t细胞、相关多核苷酸和方法
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
CA3100253A1
(en)
|
2018-05-14 |
2019-11-21 |
Immunocore Limited |
Bifunctional binding polypeptides
|
|
CN112805378A
(zh)
|
2018-08-09 |
2021-05-14 |
朱诺治疗学股份有限公司 |
用于评估整合核酸的方法
|
|
BR112021002390A2
(pt)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processos para gerar células modificadas e suas composições
|
|
JP7504891B2
(ja)
|
2018-09-11 |
2024-06-24 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞組成物のマススペクトロメトリー分析のための方法
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
WO2020089343A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
US20210393691A1
(en)
|
2018-11-06 |
2021-12-23 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
EP4427810A3
(de)
|
2018-11-30 |
2024-12-04 |
Juno Therapeutics, Inc. |
Behandlungsverfahren mit adoptiver zelltherapie
|
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
|
|
GB201901306D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Multi-domain binding molecules
|
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
|
EP3941938A1
(de)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
Für das b-zell-reifungsantigen spezifische t-zell-rezeptoren zur behandlung von krebs
|
|
GB201904328D0
(en)
|
2019-03-28 |
2019-05-15 |
Immunocore Ltd |
Specific binding molecules
|
|
CN113811329B
(zh)
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
US20220228101A1
(en)
|
2019-06-07 |
2022-07-21 |
Juno Therapeutics, Inc. |
Automated t cell culture
|
|
SG11202113356XA
(en)
|
2019-06-12 |
2021-12-30 |
Juno Therapeutics Inc |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
|
|
GB201915282D0
(en)
|
2019-10-22 |
2019-12-04 |
Immunocore Ltd |
Specific binding molecules
|
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
|
WO2021094752A1
(en)
|
2019-11-12 |
2021-05-20 |
Oxford Biomedica (Uk) Limited |
Production system
|
|
EP4070097A1
(de)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Verfahren in zusammenhang mit toxizität und ansprechen bei einer zelltherapie zur behandlung von b-zell-malignitäten
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
CA3172447A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
GB202005779D0
(en)
|
2020-04-21 |
2020-06-03 |
Scancell Ltd |
Anti-tumour immune responses
|
|
GB202006629D0
(en)
|
2020-05-05 |
2020-06-17 |
Immunocore Ltd |
Specific binding molecules
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
EP4171616A1
(de)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Manipulierte t-zellen zur bedingten expression eines rekombinanten rezeptors, zugehörige polynukleotide und verfahren
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
GB202010329D0
(en)
|
2020-07-06 |
2020-08-19 |
Immunocore Ltd |
Specific binding molecules
|
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
|
EP4232076A1
(de)
|
2020-10-20 |
2023-08-30 |
The Chancellor, Masters and Scholars of The University of Oxford |
Verfahren und zusammensetzungen zur behandlung von epstein-barr-virus-assoziiertem krebs
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
US20220168407A1
(en)
|
2020-11-05 |
2022-06-02 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
|
GB202018395D0
(en)
|
2020-11-23 |
2021-01-06 |
Scancell Ltd |
Immunotherapy
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
WO2023288203A2
(en)
|
2021-07-12 |
2023-01-19 |
Ludwig Institute For Cancer Research Ltd |
T cell receptors specific for tumor-associated antigens and methods of use thereof
|
|
KR20240137075A
(ko)
|
2022-01-28 |
2024-09-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 조성물의 제조 방법
|
|
JP2025508738A
(ja)
|
2022-02-20 |
2025-04-10 |
イムノコア リミテッド |
Ｈｉｖ特異的結合分子及びｔｃｒ
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20240002800A1
(en)
|
2022-05-16 |
2024-01-04 |
Mendus B.V. |
Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
|
KR20250061756A
(ko)
|
2022-09-08 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
KR20250133715A
(ko)
|
2023-01-06 |
2025-09-08 |
이뮤노코어 리미티드 |
Prame 펩타이드-hla 복합체에 대한 결합 분자
|
|
IL321809A
(en)
|
2023-01-06 |
2025-08-01 |
Immunocore Ltd |
Binding molecules against a piwil1 peptide-hla complex
|
|
US20260232729A1
(en)
|
2023-02-03 |
2026-08-13 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
GB202306345D0
(en)
|
2023-04-28 |
2023-06-14 |
Immunocore Ltd |
Binding molecules
|
|
EP4716851A2
(de)
|
2023-05-23 |
2026-04-01 |
Juno Therapeutics, Inc. |
Aktivierungsmarker von t-zellen und verfahren zur beurteilung der t-zellaktivierung
|
|
WO2024260454A1
(zh)
*
|
2023-06-21 |
2024-12-26 |
北京可瑞生物科技有限公司 |
经修饰的tcr恒定区及其在tcr融合蛋白中的用途
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025252840A1
(en)
*
|
2024-06-04 |
2025-12-11 |
Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern |
Half-life modulation by a tag comprising at least one constant domain of an immunoglobulin light chain
|
|
GB2641580A
(en)
|
2024-06-07 |
2025-12-10 |
T Therapeutics Ltd |
Tumour-transforming multispecific proteins
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
GB202418460D0
(en)
|
2024-12-16 |
2025-01-29 |
Univ Oxford Innovation Ltd |
Multivalent binding proteins
|
|
GB202418912D0
(en)
|
2024-12-20 |
2025-02-05 |
Immunocore Ltd |
Specific binding molecules
|